Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.

Literature DB >> 33500548

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.

Joseph E Grossman¹, Divya Vasudevan¹, Cailin E Joyce¹, Manuel Hildago².

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 33500548 PMCID： PMC7906900 DOI： 10.1038/s41388-020-01611-6

Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867

× No keyword cloud information.

12 in total

1. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors: Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal: Clin Cancer Res Date: 2012-01-23 Impact factor: 12.531

2. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors: Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal: Blood Date: 2010-07-13 Impact factor: 22.113

3. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.

Authors: Ivraym B Barsoum; Chelsea A Smallwood; D Robert Siemens; Charles H Graham
Journal: Cancer Res Date: 2013-12-13 Impact factor: 12.701

4. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Authors: Nadeem Riaz; Jonathan J Havel; Vladimir Makarov; Alexis Desrichard; Walter J Urba; Jennifer S Sims; F Stephen Hodi; Salvador Martín-Algarra; Rajarsi Mandal; William H Sharfman; Shailender Bhatia; Wen-Jen Hwu; Thomas F Gajewski; Craig L Slingluff; Diego Chowell; Sviatoslav M Kendall; Han Chang; Rachna Shah; Fengshen Kuo; Luc G T Morris; John-William Sidhom; Jonathan P Schneck; Christine E Horak; Nils Weinhold; Timothy A Chan
Journal: Cell Date: 2017-10-12 Impact factor: 41.582

5. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer.

Authors: Lei Zhang; Xin Yu; Liangtao Zheng; Yuanyuan Zhang; Yansen Li; Qiao Fang; Ranran Gao; Boxi Kang; Qiming Zhang; Julie Y Huang; Hiroyasu Konno; Xinyi Guo; Yingjiang Ye; Songyuan Gao; Shan Wang; Xueda Hu; Xianwen Ren; Zhanlong Shen; Wenjun Ouyang; Zemin Zhang
Journal: Nature Date: 2018-10-29 Impact factor: 49.962

6. Deubiquitination and Stabilization of PD-L1 by CSN5.

Authors: Seung-Oe Lim; Chia-Wei Li; Weiya Xia; Jong-Ho Cha; Li-Chuan Chan; Yun Wu; Shih-Shin Chang; Wan-Chi Lin; Jung-Mao Hsu; Yi-Hsin Hsu; Taewan Kim; Wei-Chao Chang; Jennifer L Hsu; Hirohito Yamaguchi; Qingqing Ding; Yan Wang; Yi Yang; Chung-Hsuan Chen; Aysegul A Sahin; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal: Cancer Cell Date: 2016-11-17 Impact factor: 31.743

7. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

Authors: Michal Marzec; Qian Zhang; Ami Goradia; Puthiyaveettil N Raghunath; Xiaobin Liu; Michele Paessler; Hong Yi Wang; Maria Wysocka; Mangeng Cheng; Bruce A Ruggeri; Mariusz A Wasik
Journal: Proc Natl Acad Sci U S A Date: 2008-12-16 Impact factor: 11.205

8. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors: Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal: Nat Med Date: 2002-06-24 Impact factor: 53.440

9. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Authors: Ranee Mehra; Tanguy Y Seiwert; Shilpa Gupta; Jared Weiss; Iris Gluck; Joseph P Eder; Barbara Burtness; Makoto Tahara; Bhumsuk Keam; Hyunseok Kang; Kei Muro; Ravit Geva; Hyun Cheol Chung; Chia-Chi Lin; Deepti Aurora-Garg; Archana Ray; Kumudu Pathiraja; Jonathan Cheng; Laura Q M Chow; Robert Haddad
Journal: Br J Cancer Date: 2018-06-29 Impact factor: 7.640

10. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

Authors: Angel Garcia-Diaz; Daniel Sanghoon Shin; Blanca Homet Moreno; Justin Saco; Helena Escuin-Ordinas; Gabriel Abril Rodriguez; Jesse M Zaretsky; Lu Sun; Willy Hugo; Xiaoyan Wang; Giulia Parisi; Cristina Puig Saus; Davis Y Torrejon; Thomas G Graeber; Begonya Comin-Anduix; Siwen Hu-Lieskovan; Robert Damoiseaux; Roger S Lo; Antoni Ribas
Journal: Cell Rep Date: 2017-05-09 Impact factor: 9.423

15 in total

Review 1. Targeting the DNA damage response in immuno-oncology: developments and opportunities.

Authors: Roman M Chabanon; Mathieu Rouanne; Christopher J Lord; Jean-Charles Soria; Philippe Pasero; Sophie Postel-Vinay
Journal: Nat Rev Cancer Date: 2021-08-10 Impact factor: 60.716

Review 2. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.

Authors: Hirohito Yamaguchi; Jung-Mao Hsu; Wen-Hao Yang; Mien-Chie Hung
Journal: Nat Rev Clin Oncol Date: 2022-02-07 Impact factor: 66.675

3. Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade.

Authors: Wei Wang; Taja Lozar; Athena E Golfinos; Denis Lee; Ellery Gronski; Ella Ward-Shaw; Mitchell Hayes; Justine Y Bruce; Randall J Kimple; Rong Hu; Paul M Harari; Jin Xu; Aysenur Keske; Paul M Sondel; Megan B Fitzpatrick; Huy Q Dinh; Paul F Lambert
Journal: Clin Cancer Res Date: 2022-07-01 Impact factor: 13.801

Review 4. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.

Authors: Tae Kon Kim; Esten N Vandsemb; Roy S Herbst; Lieping Chen
Journal: Nat Rev Drug Discov Date: 2022-06-14 Impact factor: 112.288

5. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.

Authors: David M O'Malley; Maryna Neffa; Bradley J Monk; Tamar Melkadze; Marilyn Huang; Anna Kryzhanivska; Iurie Bulat; Tarek M Meniawy; Andrea Bagameri; Edward W Wang; Bernard Doger de Speville Uribe; Roberto Hegg; Waldo Ortuzar Feliu; Marek Ancukiewicz; Iwona Lugowska
Journal: J Clin Oncol Date: 2021-12-21 Impact factor: 50.717

6. Precision Combination Therapies Based on Recurrent Oncogenic Coalterations.

Authors: Xubin Li; Elisabeth K Dowling; Gonghong Yan; Zeynep Dereli; Behnaz Bozorgui; Parisa Imanirad; Jacob H Elnaggar; Augustin Luna; David G Menter; Patrick G Pilié; Timothy A Yap; Scott Kopetz; Chris Sander; Anil Korkut
Journal: Cancer Discov Date: 2022-06-02 Impact factor: 38.272

Review 7. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors: Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal: Biomedicines Date: 2022-05-20